DESMOPRESSIN ACETATE | N019955 | FERRING PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Ferring Pharmaceuticals Inc. et al v. Serenity Pharmaceuticals, LLC et al 9 patentsdesmopressin | S.D.N.Y. | 2017-12-20 | Terminated 2020-08-21 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Hyman, Phelps & McNamara, P.C. FDA-2026-P-3844 · 6 docket documents Hyman, Phelps & McNamara, P.C. filed this suitability petition under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting that the FDA declare Desmopressin Acetate Tablets in 0.05 mg and 0.15 mg strengths suitable for submission as an Abbreviated New Drug Application, with the | Suitability | 2026-04-09 | Open | Hyman, Phelps & McNamara, P.C. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.3745
per ea
Lowest NADAC/Unit
$0.2386
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 69918020101DESMOPRESSIN ACETATE 0.2 MG TB | $0.3745 | EA | Generic | — | 2026-06-17 |
| 69918010101DESMOPRESSIN ACETATE 0.1 MG TB | $0.2386 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.